Results for “ ”

Entry Author Date Location
Bio Roundup: Biogen Price Fears, A Grail Billion, Hellos, Byes & More 01/06/17 National
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
Frequency, Led by MIT’s Langer, Aims to Fight Hearing Loss With Drugs 01/05/17 Boston
Neon Therapeutics Hauls in $70M for Personalized Cancer Vaccines 01/05/17 Boston
Infinity Pharma R&D Chief Adams Retires Amid Restructuring, Job Cuts 01/04/17 Boston
Edico Genome’s Deal with Dell EMC Fits Partnership Strategy 01/04/17 San Diego
RaNA Expands, Joins Messenger RNA Drug Race With Shire Deal 01/04/17 Boston
Inotek’s Glaucoma Drug Flunks in First Phase 3 Test, Shares Crumble 01/03/17 Boston
First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work 01/03/17 Boston
Varmus, Sato on Steering De Blasio’s $500M Plan to Grow NY Biotech 12/30/16 New York
Gates Foundation Sends $140M to Intarcia for HIV Version of Pump 12/29/16 Boston
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Ionis, Biogen Make History With FDA Nod for Spine Disease Drug 12/23/16 Boston
Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More 12/23/16 National
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
Despite FDA Delay, Advocates Hopeful for New Genentech MS Drug 12/21/16 San Francisco
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) 12/21/16 National
Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push 12/20/16 Boston
Biogen Promotes Vounatsos to CEO, Capping Scangos’s 6-Year Run 12/19/16 Boston
As Its Rivals Team Up, Editas Buys Next-Gen CRISPR From Old Friends 12/19/16 Boston
Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug 12/19/16 Boulder/Denver
Creating Bio “Gestalt” And Photos From New York Life Sciences 2021 12/19/16 New York
Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More 12/16/16 National
After FDA Hold, Agios Quickly Scraps One Anemia Drug, Turns to Another 12/15/16 Boston
Flagship Pioneers New Name, $285M ‘Special Opportunities’ Fund 12/15/16 Boston
Goldfinch Bio Aims $55M and Cancer Strategy at Genetic Kidney Disease 12/14/16 Boston
Proteon’s Blood Vessel Drug Flunks Main Phase 3 Test, Shares Plummet 12/13/16 Boston
NY Bio Surge Continues as De Blasio Unveils $500M, 10-Year Life Sci Plan 12/13/16 New York
New York State Hatches Sprawling $650M Plan to Foster Biotech 12/12/16 New York
BlueRock Raises $225M To Repair Heart Damage With Stem Cells 12/12/16 Boston
Page 3 of 119 « previous page · next page »